← Back to Search

Behavioral Intervention

Health services research (text messages, smart pill bottle) for Acute Myeloid Leukemia

N/A

Waitlist Available

Research Sponsored by Thomas Jefferson University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at baseline, 1, and 2 months

Awards & highlights

Study Summary

This trial tests a mobile intervention to help AML patients take their oral anti-cancer meds correctly. It may help doctors design better educational material to improve adherence.

Eligible Conditions

Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at baseline, 1, and 2 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at baseline, 1, and 2 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline, 1, and 2 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Leukemia, Myelocytic, Acute

Antibiotics, Antineoplastic

Secondary outcome measures

Complete remission (CR)

Complete Blood Count

Morphologic leukemia-free state (MLFS)

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Health services research (text messages, smart pill bottle)Experimental Treatment4 Interventions

Patients receive interactive text messages to help with adherence to medications and a smart pill bottle with medication reminders on study.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor

445 Previous Clinical Trials

145,714 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What purposes does this clinical trial seek to fulfill?

"The primary endpoint examined in this clinical trial, to be evaluated at 2 months, is the response rate of patients with acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) based on their MD Anderson Symptom Inventory score. Secondary metrics include complete remission (CR), partial remissions (PR), and morphologic leukemia-free state (MLFS). All outcomes will be analyzed using univariable logistic regression models that focus on a predictor of daily OAM medication adherence."

Answered by AI

What is the current number of participants in this trial?

"Affirmative. Clinicaltrials.gov displays that this clinical trial, initially posted on August 15th 2022 is currently recruiting patients. 30 individuals are needed between two different medical centres for the study's completion."

Answered by AI

Are participants currently being enrolled in this clinical experiment?

"As corroborated by clinicaltrials.gov, this study is still recruiting patients as of October 25th 2022. It was initially made available to the public on August 15th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute Myeloid Leukemia Patients, the txt4AML Study

2022. "Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute Myeloid Leukemia Patients, the txt4AML Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05595135.